Andrew D. Dickinson Sells 142,180 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson sold 142,180 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $12,626,253.06. The trade was a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Gilead Sciences Trading Down 0.4 %

NASDAQ GILD opened at $97.99 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $99.45. The stock has a market capitalization of $122.12 billion, a PE ratio of 1,088.78, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18. The firm has a 50 day moving average of $92.58 and a two-hundred day moving average of $86.14.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the previous year, the business posted $2.29 EPS. The firm’s revenue was up 7.0% on a year-over-year basis. As a group, research analysts expect that Gilead Sciences, Inc. will post 4.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of GILD. Algert Global LLC acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $254,000. Quarry LP acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $43,000. Centaurus Financial Inc. boosted its holdings in shares of Gilead Sciences by 12.4% in the 2nd quarter. Centaurus Financial Inc. now owns 4,798 shares of the biopharmaceutical company’s stock valued at $329,000 after buying an additional 529 shares in the last quarter. AMF Tjanstepension AB boosted its holdings in shares of Gilead Sciences by 14.7% in the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock valued at $33,645,000 after buying an additional 51,390 shares in the last quarter. Finally, Czech National Bank boosted its holdings in shares of Gilead Sciences by 6.8% in the 3rd quarter. Czech National Bank now owns 253,618 shares of the biopharmaceutical company’s stock valued at $21,263,000 after buying an additional 16,209 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price on the stock. Bank of America reiterated a “buy” rating and issued a $109.00 target price on shares of Gilead Sciences in a report on Tuesday, December 10th. Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Citigroup initiated coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target on the stock. Finally, The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $98.39.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.